IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis
Tóm tắt
The origin and role of IL-17, a T-cell derived cytokine, in cartilage and bone destruction during rheumatoid arthritis (RA) remain to be clarified. In human ex vivo models, addition of IL-17 enhanced IL-6 production and collagen destruction, and inhibited collagen synthesis by RA synovium explants. On mouse cartilage, IL-17 enhanced cartilage proteoglycan loss and inhibited its synthesis. On human RA bone explants, IL-17 also increased bone resorption and decreased formation. Addition of IL-1 in these conditions increased the effect of IL-17. Blocking of bone-derived endogenous IL-17 with specific inhibitors resulted in a protective inhibition of bone destruction. Conversely, intra-articular administration of IL-17 into a normal mouse joint induced cartilage degradation. In conclusion, the contribution of IL-17 derived from synovium and bone marrow T cells to joint destruction suggests the control of IL-17 for the treatment of RA.
Tài liệu tham khảo
Arend WP: The pathophysiology and treatment of rheumatoid arthritis. Arthritis Rheum. 1997, 40: 595-597.
Chizzolini C, Chicheportiche R, Burger D, Dayer JM: Human Th1 cells preferentially induce interleukin (IL)-1beta while Th2 cells induce IL-1 receptor antagonist production upon cell/cell contact with monocytes. Eur J Immunol. 1997, 27: 171-177.
Chomarat P, Rissoan MC, Pin JJ, Banchereau J, Miossec P: Contribution of IL-1, CD 14, CD 13 in the increased IL-6 production during monocyte synoviocyte interactions. J Immunol. 1995, 155: 3645-3652.
Manolagas SC: Role of cytokines in bone resorption. Bone. 1995, 17: 63S-67S. 10.1016/8756-3282(95)00180-L.
Lader CS, Flanagan AM: Prostaglandin E2, interleukin-1a, and tumor necrosis factor-α, increase human osteoblast formation and bone resorption in vitro. Endocrinology. 1998, 139: 3157-3164.
Horwood NJ, Kartsogiannis V, Quinn JM, Romas E, Martin TJ, Gillespie MT: Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun. 1999, 265: 144-150. 10.1006/bbrc.1999.1623.
Van de Loo AAJ, Van den Berg WB: Effects of murine recombinant interleukin-1 on synovial joints in mice; measurement of patella cartilage metabolism and joint inflammation. Ann Rheum Dis. 1990, 49: 238-245.
Ghivizzani SC, Kang R, Georgescu HI, Lechman ER, Jaffurs D, Engle JM, Watkins SC, Tindal MH, Suchanek MK, McKenzie LR, Evans CH, Robbins PD: Constitutive intra-articular expression of human IL-1 beta following gene transfer to rabbit synovium produces all major pathologies of human rheumatoid arthritis. J Immunol. 1997, 159: 3604-3612.
Arend WP, Dayer J-M: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum. 1995, 38: 151-160.
Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997, 337: 141-147. 10.1056/NEJM199707173370301.
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998, 41: 1548-1551. 10.1002/1529-0131(199803)41:3<565::AID-ART28>3.3.CO;2-#.
Bresnihan B, Alvaro-Garcia J-M, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Rozman B, Watt I, Williams B, Aitchison R, McCabe D, Musikic P: Treatment of rheumatoid arthritis with recombinant interleukin-1 receptor antagonist. Arthritis Rheum. 1998, 41: 2196-2104. 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.3.CO;2-U.
Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999, 402: 304-309. 10.1038/46303.
Horwood NJ, Udagawa N, Elliott J, Grail D, Okamura H, Kurimoto M, Dunn AR, Martin T, Gillespie MT: Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J Clin Invest. 1998, 101: 595-603.
Weitzmann MN, Cenci S, Rifas L, Brown C, Pacifici R: Interleukin-7 stimulates osteoclast formation by upregulating the T-cell production of soluble osteoclastogenic cytokines. Blood. 2000, 96: 1873-1878.
Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, Pin JJ, Garrone P, Garcia E, Saeland S, Blanchard D, Gaillard C, Das Mahapatra B, Rouvier E, Golstein P, Banchereau J, Lebecque S: T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med. 1996, 183: 2593-2603.
Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, Miossec P: Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 1999, 42: 963-970. 10.1002/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E.
Aarvak T, Chabaud M, Miossec P, Natvig JB: IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol. 1999, 162: 1246-1251.
Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T: IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 1999, 103: 1345-1352.
Van Bezooijen RL, Farih-Sips HC, Papapoulos SE, Löwik CW: Interleukin-17: a new bone acting cytokine in vitro. J Bone Miner Res. 1999, 14: 1513-1521.
Chabaud M, Fossiez F, Taupin JL, Miossec P: IL-17 enhances the effects of IL-1 on IL-6 and LIF production by rheumatoid arthritis synoviocytes. J Immunol. 1998, 161: 409-414.
Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR, Cohen JI, Spriggs MK: Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity. 1995, 3: 811-821.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Pries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Nenstadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GC: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324.
Miossec P, Briolay J, Dechanet J, Wijdenes J, Martinez-Valdez H, Banchereau J: Interleukin 4 inhibits ex vivo production of proinflammatory cytokines and immunoglobulins by rheumatoid synovitis. Arthritis Rheum. 1992, 35: 874-883.
Miossec P, Chomarat P, Dechanet J, Moreau J-F, Roux J-P, Delmas P, Banchereau J: Interleukin 4 inhibits bone resorption through an effect on osteoclasts and proinflammatory cytokines in an ex vivo model of bone resorption in rheumatoid arthritis. Arthritis Rheum. 1994, 37: 1715-1722.
Bonde M, Garnero P, Fledelius C, Qvist P, Delmas PD, Christiansen C: Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J Bone Miner Res. 1997, 12: 1028-1034.
Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD: Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996, 11: 337-349.
Abrams JS, Roncarolo M-G, Yssel H, Andersson U, Gleich GJ, Silver JE: Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev. 1992, 127: 5-24.
Lubberts E, Joosten LAB, Helsen MMA, Van den Berg WB: Regulatory role of interleukin-10 in joint inflammation and cartilage destruction in murine streptococcal cell wall (SCW) arthritis. Murine therapeutic benefit with IL-4/IL-10 combination therapy than with IL-10 treatment alone. Cytokine. 1998, 10: 361-369. 10.1006/cyto.1997.0298.
van Beuningen HM, Arntz OJ, van den Berg WB: Insulin-like growth factor stimulation of articular chondrocyte proteoglycan synthesis. Availability and responses at different ages. Br J Rheumatol. 1993, 32: 1037-1043.
Awane M, Andres PG, Li DJ, Reinecker HC: NF-kappa B-inducing kinase is a common mediator of IL-17-, TNF-alpha-, and IL-1 beta-induced chemokine promoter activation in intestinal epithelial cells. J Immunol. 1999, 162: 5337-5344.
Jovanovic DV, DiBattista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, Mineau F, Pelletier JP: IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol. 1998, 160: 3513-3521.
Aarvak T, Chabaud M, Kallberg E, Miossec P, Natvig JB: Change in the Th1/Th2 phenotype of memory T-cell clones from rheumatoid arthritis synovium. Scand J Immunol. 1999, 50: 1-9. 10.1046/j.1365-3083.1999.00581.x.
Vey E, Burger D, Dayer JM: Expression and cleavage of tumor necrosis factor-alpha and tumor necrosis factor receptors by human monocytic cell lines upon direct contact with stimulated T cells. Eur J Immunol. 1996, 26: 2404-2409.
Chabaud M, Garnero P, Dayer JM, Guerne PA, Fossiez F, Miossec P: Contribution of interleukin-17 to synovium matrix destruction in rheumatoid arthitis. Cytokine. 2000, 12: 1092-1099. 10.1006/cyto.2000.0681.
Attur MG, Patel RN, Abramson SB, Amin AR: Interleukin-17 upregulation of nitric oxide production in human osteoarthritis cartilage. Arthritis Rheum. 1997, 40: 1050-1053.
Shalom-Barak T, Quach J, Lotz M: Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-kappaB. J Biol Chem. 1998, 273: 27467-27473. 10.1074/jbc.273.42.27467.
Dudler J, Renggli-Zulliger N, Busso N, Lotz M, So A: Effect of interleukin 17 on proteoglycan degradation in murine knee joints. Ann Rheum Dis. 2000, 59: 529-532. 10.1136/ard.59.7.529.
John V, Hock JM, Short LL, Glasebrook AL, Galvin RJ: A role for CD8+ T lymphocytes in osteoclast differentiation in vitro. Endocrinology. 1996, 137: 2457-2463.
Kong YY, Boyle WJ, Penninger JM: Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development. Immunol Cell Biol. 1999, 77: 188-193. 10.1046/j.1440-1711.1999.00815.x.
Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, Goldring SR: Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000, 43: 250-258. 10.1002/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P.
Romas E, Bakharevski O, Hards DK, Kartsogiannis V, Quinn JM, Ryan PF, Martin TJ, Gillespie MT: Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum. 2000, 43: 821-826. 10.1002/1529-0131(200004)43:4<821::AID-ANR12>3.0.CO;2-T.
Lubberts E, Joosten LA, Chabaud M, van Den Bersselaar L, Oppers B, Coenen-De Roo CJ, Richards CD, Miossec P, van Den Berg WB: IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest. 2000, 105: 1697-1710.